Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer

The expected effect of androgen-deprivation therapy is one of the important criteria when choosing therapy in patients with prostate cancer. No less significant factor is the time of its implementation. The study showed that high expression of androgen receptors (AR) in the tumor tissue against the background of low estrogen receptor α (ERα) expression is characteristic of patients in whom the effect of androgen-deprivation therapy was observed for 12 months. A set of parameters has been identified that makes it possible to predict the duration of response to androgen-deprivation therapy in patients with prostate cancer, which include the patient’s age, testosterone level, prostate specific antigen, expression level of AR, ERα. These data allow us to consider these parameters as additional informative markers, to predict not only the expected effect, but also its duration.

1. Markova A.S., Polikarpova S.B., Kamolov B.S. et al. Predictors of overall survival in patients with metastatic castration-resistant prostate cancer. Onkourologiya = Cancer Urology 2015;11(2):77—84.(In Russ.).

2. Amiya Y., Yamada Y., Sugiura M. et al. Treatment of locally advanced prostate cancer (Stage T3). Jpn J Clin Oncol 2017;47(3):257—61. DOI: 10.1093/jjco/hyw186. PMID: 28096182.

3. Wang Y., Kreisberg J.I., Ghosh P.M. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007;7(6):591—604. PMID: 17896924.

4. D’Amico A.V., Moul J., Carroll P.R. et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004;172(5 Pt 2):42-6. PMID: 15535442.

5. Lonergan P.E., Tindall D.J. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011;10:20. DOI: 10.4103/1477-3163.83937. PMID: 21886458.

6. Al-Maghrabi J.A., Hassan T.M., Abdel-Meguid T.A., Mosli H.A. Original article expression of estrogen alpha and beta receptors in prostate cancer and hyperplasia: immunohistochemical analysis. African J Urol 2010;16(3):1110—5704.

7. Karamouzis M.V., Papavassiliou K.A., Adamopoulos C., Papavassiliou A.G. Targeting androgen/estrogen receptors crosstalk in cancer. Trends Cancer 2016;2(1):35—48. DOI: 10.1016/j.trecan.2015.12.001. PMID: 28741499.

8. Takizawa I., Lawrence M.G., Balanathan P. et al. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget 2015;6(2):604—16. DOI: 10.18632/oncotarget.2820. PMID: 25436982.

9. Ahmad N., Kumar R. Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett 2011;300(1):1—9. DOI: 10.1016/j.canlet.2010.09.008. PMID: 20926181.

10. Nelson A.W., Tilley W.D., Neal D.E., Carroll J.S. Estrogen receptor beta in prostate cancer: friend or foe? Endocr Relat Cancer 2014;21(4):T219-34. DOI: 10.1530/ERC-13-0508. PMID: 24402043.

11. Spirina L.V., Gorbunov A.K., Kondakova I.V et al. TRIM16 transcription factor in prostate cancer, association with the expression of estrogen and androgen receptors and clinical and morphological features of the disease. Buulleten’ sibirskoy meditsiny = Bulletin of Siberian Medicine 2018;17(3):122—30. (In Russ.).

12. Hearn J.W.D., AbuAli G., Reichard C.A. et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 2016;17(10):1435—44. DOI: 10.1016/S1470-2045(16)30227-3. PMID: 27575027.

13. Geara F.B., Bulbul M., Khauli R.B. et al. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation. Radiat Oncol 2017;12(1):149. DOI: 10.1186/s13014-017-0884-y. PMID: 28882187.

14. Michaud J.E., Billups K.L., Partin A.W. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol 2015;7(6): 378—87. DOI: 10.1177/1756287215597633. PMID: 26622322.

15. Pechersky A.V., Semiglazov V.F., Komyakov B.K. et al. Change in steroid receptors expression in partial androgen deficiency of the ageing male (PADAM). Tsytologiya = Cytology 2005;47(4):311—6. (In Russ.).